FDA approves Lundbeck's migraine prevention therapy

The U.S. Food and Drug Administration approved Lundbeck A/S' migraine prevention therapy, which the Danish drugmaker acquired through its near $2 billion deal for Alder BioPharmaceuticals in 2019, the company said on Friday.

from Reuters: Health News https://ift.tt/3bY2tW4